Insmed Inc (INSM)vsRigel Pharmaceuticals Inc (RIGL)
INSM
Insmed Inc
$148.31
+6.59%
HEALTHCARE · Cap: $29.99B
RIGL
Rigel Pharmaceuticals Inc
$26.29
+0.61%
HEALTHCARE · Cap: $489.54M
Smart Verdict
WallStSmart Research — data-driven comparison
Insmed Inc generates 106% more annual revenue ($606.42M vs $294.28M). RIGL leads profitability with a 124.7% profit margin vs -2.1%. RIGL earns a higher WallStSmart Score of 79/100 (B+).
INSM
Hold39
out of 100
Grade: F
RIGL
Strong Buy79
out of 100
Grade: B+
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Intrinsic value data unavailable for INSM.
Margin of Safety
+96.2%
Fair Value
$911.66
Current Price
$26.29
$885.37 discount
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
No standout strengths identified
Attractively priced relative to earnings
Reasonable price relative to book value
Keeps 125 of every $100 in revenue as profit
Strong operational efficiency at 33.2%
Revenue surging 21.2% year-over-year
Areas to Watch
1.5% revenue growth
0.0% earnings growth
Trading at 43.0x book value
ROE of -2.5% — below average capital efficiency
Smaller company, higher risk/reward
ROE of 1.9% — below average capital efficiency
Comparative Analysis Report
WallStSmart ResearchBull Case : INSM
PEG of 1.09 suggests the stock is reasonably priced for its growth.
Bull Case : RIGL
The strongest argument for RIGL centers on P/E Ratio, Price/Book, Profit Margin. Profitability is solid with margins at 124.7% and operating margin at 33.2%. Revenue growth of 21.2% demonstrates continued momentum.
Bear Case : INSM
The primary concerns for INSM are Revenue Growth, EPS Growth, Price/Book.
Bear Case : RIGL
The primary concerns for RIGL are Market Cap, Return on Equity.
Key Dynamics to Monitor
INSM profiles as a turnaround stock while RIGL is a growth play — different risk/reward profiles.
RIGL carries more volatility with a beta of 1.17 — expect wider price swings.
RIGL is growing revenue faster at 21.2% — sustainability is the question.
RIGL generates stronger free cash flow (22M), providing more financial flexibility.
Bottom Line
RIGL scores higher overall (79/100 vs 39/100), backed by strong 124.7% margins and 21.2% revenue growth. Both earn "Strong Buy" and "Hold" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Insmed Inc
HEALTHCARE · BIOTECHNOLOGY · USA
Insmed Incorporated, a biopharmaceutical company, develops and markets therapies for patients with rare and serious diseases. The company is headquartered in Bridgewater, New Jersey.
Rigel Pharmaceuticals Inc
HEALTHCARE · BIOTECHNOLOGY · USA
Rigel Pharmaceuticals, Inc., a biotechnology company, discovers and develops small molecule drugs to treat blood disorders, cancer, and rare immune diseases. The company is headquartered in South San Francisco, California.
Compare with Other BIOTECHNOLOGY Stocks
Want to dig deeper into these stocks?